<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345746</url>
  </required_header>
  <id_info>
    <org_study_id>12-19</org_study_id>
    <nct_id>NCT02345746</nct_id>
  </id_info>
  <brief_title>Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis</brief_title>
  <official_title>Phase 2 Study of Hepatic Arterial Infusion With Oxaliplatin, Folinic Acid and 5 Fluorouracil Alone or in Combination With Intravenous Chemotherapy in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, Hepatic Arterial Infusion will be combined with systemic therapy for patients&#xD;
      with liver-only or liver-predominant metastases who have failed at least one line of systemic&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II study, investigators will combine the HAI with systemic therapy for patients&#xD;
      with liver-only or liver-predominant metastases who have failed at least one line of systemic&#xD;
      chemotherapy. We hypothesize that combination therapy will be able to convert some patients&#xD;
      to surgical resection candidates, or/and to overcome chemo-resistance of liver metastases to&#xD;
      systemic i.v. chemotherapy for some clinically fit, heavily pre-treated patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    patient population&#xD;
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine response rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Hepatic Artery Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>infusion over 12 hours via HAI</description>
    <arm_group_label>Hepatic Artery Infusion</arm_group_label>
    <other_name>Eloxatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>as a 2-hour infusion via HAI on day 2</description>
    <arm_group_label>Hepatic Artery Infusion</arm_group_label>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3</description>
    <arm_group_label>Hepatic Artery Infusion</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Performance status ECOG 0-2 and a life expectancy of &gt;3 months.&#xD;
&#xD;
          2. Patients were required to have measurable disease in the liver, defined as lesions&#xD;
             measuring &gt;1 cm in largest diameter on spiral-computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI)&#xD;
&#xD;
          3. Histologically confirmed metastatic advanced solid tumors involving the liver, liver&#xD;
             replacement less than 70%&#xD;
&#xD;
          4. No bevacizumab (avastin) use within 4 weeks prior to enrollment.&#xD;
&#xD;
          5. Absence of portal vein thrombosis&#xD;
&#xD;
          6. Not a surgical candidate or patients refuse surgery&#xD;
&#xD;
          7. Loss of response to at least two lines of systemic chemotherapy including FU,&#xD;
             Oxaliplatin or irinotecan in metastatic setting&#xD;
&#xD;
          8. An asymptomatic extra-hepatic disease is allowed, provided that the extent of the&#xD;
             metastatic disease in the liver represented the bulk of the metastatic disease.&#xD;
&#xD;
          9. History of liver-directed therapy is eligible at the investigator's discretion.&#xD;
&#xD;
         10. Adequate renal function with a calculated creatinine clearance greater than 60 mL/min.&#xD;
&#xD;
         11. Hepatic function as follows: Total Bilirubin ≤3 mg/dL, AST ≤5 times upper normal&#xD;
             reference value, or ALT ≤ 5 times upper normal reference value.&#xD;
&#xD;
         12. Adequate bone marrow function (ANC ≥1500 cells/uL; PLT ≥ 100,000 cells/uL) before each&#xD;
             therapy.&#xD;
&#xD;
         13. At least three weeks from previous immunotherapy, chemotherapy or radiotherapy before&#xD;
             being enrolled in this study.&#xD;
&#xD;
         14. All females in childbearing age MUST have a negative serum HCG test unless patients&#xD;
             have prior hysterectomy. Women of childbearing potential must take adequate&#xD;
             precautions to prevent pregnancy during treatment.&#xD;
&#xD;
         15. Patient consent must be obtained prior to entrance onto study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical or radiographic evidence of moderate amount of ascites.&#xD;
&#xD;
          2. History of cirrhosis with Child-Pugh class B or C.&#xD;
&#xD;
          3. Pregnant or lactating females.&#xD;
&#xD;
          4. Inability to complete informed consent process and adhere to protocol treatment plan&#xD;
             and follow-up requirements.&#xD;
&#xD;
          5. Patients receiving any other investigational agents.&#xD;
&#xD;
          6. Patients with bleeding diathesis (clinical bleeding, prothrombin time =/&gt; 1.5 X upper&#xD;
             institutional normal value, INR =/&gt; 1.5, activated partial thromboplastin time aPTT&#xD;
             =/&gt; 1.5 X upper institutional normal value), active gastric or duodenal ulcer.&#xD;
&#xD;
          7. History of thrombophilia, recurrent DVTs, diagnosis of phospholipid syndrome.&#xD;
&#xD;
          8. Past or current history of malignancy other than colon cancer with the exception of&#xD;
             treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers&#xD;
             cured by local therapy alone and a DFS ≥5 years.&#xD;
&#xD;
          9. Concurrent severe illness such as active infection, or psychiatric illness/social&#xD;
             situations that would limit safety and compliance with study requirements.&#xD;
&#xD;
         10. Patients with clinically significant cardiovascular disease: myocardial infarction or&#xD;
             unstable angina within 6 months, New York Heart Association Grade II or greater&#xD;
             congestive heart failure, serious cardiac arrhythmia requiring medication, unstable&#xD;
             angina pectoris, clinically significant peripheral vascular disease&#xD;
&#xD;
         11. Patients have untreated brain metastasis or leptomeningeal metastases requiring&#xD;
             immediate intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiaxin Niu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Regional Medical Center</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Jordan Waypa</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

